Thus, anti-EGF-R monoclonal antibodies (cetuximab and panitumumab) and an anti-VEGF-A monoclonal antibody (bevacizumab) are mainly used as therapies for colorectal cancer patients [31]. This evidence concerns the gene VEGFA and colorectal cancer.